Skip NavigationSkip to Content

Design and Synthesis of Isonucleosides Constructed on a 2-Oxa-6-thiabicyclo[3.2.0]heptane Scaffold

  1. Author:
    Yoshimura, Y.
    Asami, K.
    Imamichi, T.
    Okuda, T.
    Shiraki, K.
    Takahata, H.
  2. Author Address

    [Yoshimura, Yuichi; Asami, Kazuhiro; Takahata, Hiroki] Tohoku Pharmaceut Univ, Aoba Ku, Sendai, Miyagi 9818558, Japan. [Imamichi, Tomozumi] Sci Applicat Int Corp Frederick Inc, Lab Human Retrovirol, Appl & Dev Res Program, NIAID, Frederick, MD 21702 USA. [Okuda, Tomoko; Shiraki, Kimiyasu] Toyama Univ, Dept Virol, Toyama 9300194, Japan.;Yoshimura, Y, Tohoku Pharmaceut Univ, Aoba Ku, 4-4-1 Komatsushima, Sendai, Miyagi 9818558, Japan.;yoshimura@tohoku-pharm.ac.jp
    1. Year: 2010
    2. Date: Jun
  1. Journal: Journal of Organic Chemistry
    1. 75
    2. 12
    3. Pages: 4161-4171
  2. Type of Article: Article
  3. ISSN: 0022-3263
  1. Abstract:

    A novel method for the design and synthesis of an isonucleoside containing a 2-oxa-6-thiobicyclo[3.2.0]heptane skeleton is described. 2,2-Dimethy1-1,3-dioxan-5-one 13 was converted into a dioxabicyclohexane derivative in six steps. After cleavage of the epoxide group with a thiol (thiophenol or PM B mercaptan), the resulting product was subjected to the Mitsunobu reaction in the presence of a nucleobase. The reaction proceeded via the migration of the thiosullide groups and gave the desired isonucleoside derivatives. In the case of a phenyl sulfide derivative, radical desulfurization followed by deprotection gave 4'-substituted 2',3'-dideoxyisonucleosides. A PM B sulfide derivative, on the other hand, was converted into the corresponding dimesylate, which was then treated with mercury acetate and trifluoroacetic acid to remove the PM B group. The resulting thiol derivative was treated with DBU to give the desired isonucleoside constructed on a 2-oxa-6-thiobicyclo[3.2.0]heptane scaffold after deprotection. The optimized conformer of the isonucleoside was calculated using DFT at the B3LYP/6-31G** level and was compared with that of lamivudine using model compounds.

    See More

External Sources

  1. DOI: 10.1021/jo100556u
  2. WOS: 000278560700024

Library Notes

  1. Fiscal Year: FY2009-2010
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel